Review
Biochemistry & Molecular Biology
Rodrigo C. C. De Marco, Hector J. J. Monzo, Paivi M. Ojala
Summary: With the continuous advancements in immunotherapy and precision medicine, adoptive cell therapy (ACT) has emerged as a new treatment approach in oncology. Chimeric antigen receptor (CAR) T cells, genetically modified lymphocytes, have shown promising results in targeting and killing cancer cells. Commercialization of CAR T cell therapy has paved the way for future bright developments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Taewoong Choi, Yubin Kang
Summary: Although treatment outcomes for multiple myeloma patients have greatly improved in the past two decades, the disease remains incurable. New immunotherapies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy, have emerged to treat multiple myeloma. This article provides a comprehensive review of the clinical efficacy, safety, and potential resistance mechanisms of current myeloma CAR-T therapies, with a focus on B Cell Maturation Antigen (BCMA) as the most successful target. The article also discusses novel strategies to enhance the effectiveness of myeloma CAR-T therapy.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Oncology
Elien De Bousser, Nico Callewaert, Nele Festjens
Summary: T cell-engaging immunotherapy aims to activate cytotoxic T cells to destroy cancer cells, while CAR T cell therapy redirects immune cells to recognize tumor antigens. Despite success, challenges such as toxicities and limited efficacy need to be addressed for the broad use of CAR T cell therapy. Research is ongoing to develop more powerful CAR T cells.
Review
Immunology
Peng Zhang, Yang Zhang, Nan Ji
Summary: Glioblastoma (GBM) is a deadly brain cancer with limited efficacy of standard treatments, necessitating the development of new therapies. Chimeric antigen receptor T (CAR-T) cell immunotherapy has shown success in hematological malignancies, but has not yet yielded promising results in GBM. CAR-T cell therapy for GBM faces challenges including tumor heterogeneity, immunosuppressive microenvironment, and cell persistence.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Simone Thomas, Hinrich Abken
Summary: Chimeric antigen receptors (CARs) in the second generation format provide two signals for T cell activation. However, CAR T cell persistence is limited and can be improved by supplementing cytokines as the third signal. Recent progress in understanding receptor signaling allows for the engineering of cytokines to selectively stimulate CAR T cells. We discuss strategies for engineering cytokine help intensified CAR (CHIC) T cells for adoptive cell therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemical Research Methods
Cuilin Zhang, Qiuyu Zhuang, Jingfeng Liu, Xiaolong Liu
Summary: Synthetic biology is an interdisciplinary research area that uses engineering principles to design and construct biological systems for practical applications. Chimeric antigen receptor (CAR) T cells, as one of the most successful clinical applications of synthetic biology, have shown tremendous success in treating blood malignancies. However, there are still limitations to CAR T cell therapy, hence the need for innovative CAR design becomes urgent.
ACS SYNTHETIC BIOLOGY
(2022)
Article
Oncology
P. Connor Johnson, Caron Jacobson, Alisha Yi, Mahmoud R. Gaballa, Nora Horick, Dustin J. Rabideau, Kevin Lindell, Gabriel D. DePinho, Areej R. El-Jawahri, Matthew J. Frigault
Summary: A retrospective analysis of 235 patients receiving CAR T-cell therapy found that bridging therapy use was not associated with differences in overall response, complete response rate, or progression-free survival, but was associated with worse overall survival. Additional poor prognostic factors may contribute to this association, highlighting the need for innovative bridging therapy regimens for these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Neurosciences
Lisa Feldman, Christine Brown, Behnam Badie
Summary: Glioblastoma is the most common and aggressive primary brain tumor in adults, and current mainstay treatments are ineffective, leading to the development of immunotherapy strategies. CAR T cell therapy uses genetically modified T cells to target tumor-associated antigens and has the potential to destroy tumor cells.
NEUROMOLECULAR MEDICINE
(2022)
Review
Cell Biology
Tahereh Soltantoyeh, Behnia Akbari, Amirali Karimi, Ghanbar Mahmoodi Chalbatani, Navid Ghahri-Saremi, Jamshid Hadjati, Michael R. Hamblin, Hamid Reza Mirzaei
Summary: Metastatic melanoma is a highly aggressive and difficult to treat type of skin cancer, but new therapies like CAR T cell therapy offer hope for patients. However, challenges such as off-target toxicity and therapy resistance need to be addressed through combination approaches.
Review
Oncology
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos, Wilfred T. V. Germeraad
Summary: NK cells, especially CAR-NK cells, play a crucial role in cancer treatment. Advances in CAR-NK technology show promising potential in efficiently targeting cancer cells with reduced side effects. These developments contribute to improving cancer treatment strategies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Jingting Min, Chirong Long, Lu Zhang, Jiakang Duan, Honglian Fan, Fei Chu, Zhenghong Li
Summary: Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy, and CAR-T cell therapy targeting c-Met shows potential as a therapeutic strategy. In vitro and in vivo experiments demonstrated that c-Met CAR-T cells exhibit enhanced cytotoxicity against NSCLC cells.
Article
Immunology
Rui Zheng, Yuankun Chen, Yiting Zhang, Sixin Liang, Xiaojuan Zhao, Yiyi Wang, Pengju Wang, Ruotong Meng, Angang Yang, Bo Yan
Summary: Our study explores the effect of low-affinity CARs using humanized scFvs on the function of CAR-T cells. We find that moderately reducing the affinity of CARs can maintain anti-tumor efficacy and improve the safety of CAR therapy both in vitro and in vivo. In addition, T cells expressing the VL domain only antibody show long-lasting tumor elimination capability and lower cytokine levels.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli, Ugo De Giorgi
Summary: To date, various therapeutic strategies, including immunotherapies, have been successful in prolonging the survival of breast cancer patients. Our article focuses on the application of chimeric antigen receptor-based immunotherapy in breast cancer.
Article
Oncology
Christopher A. Pennell, Heather Campbell, Meghan D. Storlie, Sara Bolivar-Wagers, Mark J. Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S. Young, Bruce R. Blazar
Summary: Current FDA-approved CAR-T cell therapies for B-cell malignancies are effective but can increase morbidity and mortality. This study compared the performances of regulatable and constitutively active CAR-T cells, and found that regulatable CAR-T cells have the potential for improved efficacy and reduced toxicity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Antonio Nenna, Myriam Carpenito, Camilla Chello, Pierluigi Nappi, Ombretta Annibali, Bruno Vincenzi, Francesco Grigioni, Massimo Chello, Francesco Nappi
Summary: CAR-T therapy has revolutionized the treatment of hematologic malignancies, but it also carries the risk of cardiotoxicity. Prompt diagnosis and treatment are crucial to improve outcomes and reduce cardiovascular complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Medical Laboratory Technology
Van Schandevyl Steven, Coorevits Liselotte, Boelens Jerina, Traen Ans, Binge Luc, Praet Marleen, Van Dorpe Jo, Padalko Elizaveta
DIAGNOSTIC CYTOPATHOLOGY
(2019)
Editorial Material
Cardiac & Cardiovascular Systems
Steven Van Schandevyl, Robbe Waterschoot, Nicolas De Vos, Daniel Devos, Ingeborg Goethals
JOURNAL OF CARDIOVASCULAR MEDICINE
(2020)